This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Veterinary CAR Immune Cell Gene Editing
The objective of veterinary Chimeric Antigen Receptor (CAR) immune cell therapy is to transform immune cells into specialized killer cells that target tumor-specific antigens through genetic engineering technology. This approach aims to enhance the specificity and efficacy of treatments for sick animals. It represents a promising therapeutic strategy for blood system tumors and certain solid tumors that are prone to relapse and challenging to treat in pets. BioVenic leverages years of expertise in animal cell gene editing, along with advancements in technology and facilities, to offer customized solutions to several critical challenges currently faced by CAR cell therapy. Our gene editing team employs cutting-edge technologies, such as CRISPR, to modify animal cells at the genomic level. Whether utilizing a gene editing system to generate CAR cells or employing base editing and gene knock-in and knock-out techniques to optimize effective cells in veterinary therapy, we are committed to providing global researchers with experimental design and implementation support to ensure feasibility and scientific rigor.
Fig.1 Schematic Illustration of Different Gene Delivery Methods to Generate CAR-T Cells.1,2
Chimeric Antigen Receptor Cell Generation Solution
BioVenic offers comprehensive solutions for the generation of CAR cells, including the production of veterinary CAR cells and the development of allogeneic CAR T cells. Our state-of-the-art technology guarantees the creation of highly effective CAR cells customized to meet your specific research requirements.
Chimeric Antigen Receptor Cell Engineering Solution
Our CAR cell engineering solutions are designed to enhance the functionality and longevity of veterinary CAR T cells. We provide advanced modification technologies to prevent CAR T cell exhaustion and improve effector functions, along with strategies to prevent fratricide during CAR cell manufacturing.
Animal Immune Cell Gene Editing Technology
BioVenic's gene-editing platform is designed to comprehensively address the unique needs of veterinary immune cell therapy development. By integrating cutting-edge genome engineering techniques, BioVenic enhances the precision and efficacy of immune cell modifications, creating robust therapeutic solutions for various research challenges.
- CRISPR/Cas9
The most conventional method used for genome editing. CRISPR/Cas9 utilizes a guide RNA to direct the Cas9 nuclease to a specific DNA sequence, allowing for precise cuts and modifications.
- CRISPR/Cas12a (Cpf1)
Cas12a differs from Cas9 by requiring fewer components and being able to create staggered cuts in DNA, offering an alternative specificity and potentially reduced off-target effects.
- CRISPR/Cas13
Unlike Cas9 and Cas12a, which target DNA, Cas13 targets RNA. This feature is leveraged for applications that require transient modifications or interventions without permanent genome alterations.
- Base Editors
Base editors are engineered proteins that enable the direct, irreversible conversion of one DNA base pair to another (e.g., C to T or A to G) without inducing double-strand breaks.
Applications of Gene Editing in Veterinary Immune Cell Therapy Development
| Knockout of Inhibitory Molecules Affecting Immune Cell Function | Tumor cells can suppress immune responses or evade destruction by immune cells by expressing negative regulatory molecules known as immune checkpoints. The activation of signaling pathways associated with these critical immune checkpoint molecules can significantly inhibit T cell proliferation and overall immune response. CRISPR technology regulates the function of immune cells in animals by knocking out inhibitory factors. |
| Construction of Anti-Suicide CAR-T Cells | CRISPR/Cas technology targets key molecules in T cells to mitigate the risk of rejection associated with CAR-T therapy in allogeneic treatments and to prevent mutual destruction. The advancement of anti-suicide veterinary CAR-T technology will be highly significant for the treatment of relapsed and refractory blood disorders and tumors. |
| Preparation of Universal CAR-T Cells | Universal CAR-T cells can be prepared using T cells from healthy animals and can also be mass-produced, resulting in improved product uniformity. This advancement significantly broadens the application scope of veterinary CAR-T cell immunotherapy. CRISPR/Cas gene knockout technology is the leading method for the development and application of universal CAR-T cells. |
| Knockout of Cytokines in CAR Cells | Utilize CRISPR/Cas technology to knock out specific cytokine genes in CAR cells, thereby reducing cytokine secretion without compromising the essential functions of CAR cells. This approach may even enhance therapeutic efficacy. |
Why Choose Us?
Precision and Efficacy
Our gene editing techniques ensure high precision in editing immunotherapeutic cells. This precision minimizes off-target effects and maximizes the efficacy of the generated CAR cells.
Comprehensive Solutions
BioVenic provides comprehensive solutions designed to meet the diverse research needs of veterinary immunotherapy. Our services range from the generation of CAR cells to the development of universal CAR T-cells, encompassing a wide array of gene editing applications to ensure robust support for your projects.
Cutting-Edge Technology
Utilizing the latest advancements in gene editing, including CRISPR-based editing systems and base editors, BioVenic offers cutting-edge solutions to enhance the development of CAR cells by improving survival rates, reducing cell exhaustion, and preventing self-targeted cytotoxicity during production.
BioVenic specializes in utilizing advanced gene editing platforms to enhance the development of veterinary immunotherapies. Our customized solutions ensure optimal immune cell performance, providing accuracy and efficiency. Whether your goal is to prevent CAR T-cell exhaustion or to avoid self-targeted cytotoxicity during production, BioVenic is here to assist. Contact us for further discussion to navigate the challenges of gene editing in the development of innovative veterinary immunotherapies.
References
- Image retrieved from Figure 1 "Schematic illustration of different gene delivery methods." Breman and Matteo, 2024, used under [CC BY 4.0] (https://creativecommons.org/licenses/by/4.0/). The original title was changed to "Schematic Illustration of Different Gene Delivery Methods to Generate CAR-T Cells."
- Breman, Eytan, and Matteo Rossi. "Engineering strategies to safely drive CAR T cells into the future." Frontiers in Immunology 15: 1411393.